MELA Sciences

company

About

MELA Sciences is a medical device company focused on the design, development and commercialization of non-invasive tools to provide

  • 51 - 100

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$20M
Industries
Health Care,Medical Device,Product Design
Founded date
Jan 1, 1989
Number Of Employee
51 - 100
Operating Status
Active

MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$30M
MELA Sciences has raised a total of $30M in funding over 2 rounds. Their latest funding was raised on Jan 1, 2015 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 1, 2015 Post-IPO Debt $10M 1 Hercules Capital Detail
Dec 1, 2014 Post-IPO Debt $20M 1 Hercules Capital Detail

Investors

Number of Lead Investors
Number of Investors
2
1
MELA Sciences is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt